Antipsychotic Augmentation vs Monotherapy in Schizophrenia

GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.

Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.

The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.

Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.

Cingulate shares plans to resubmit its ADHD candidate CTx-1301 to the FDA, following a CRL tied to CMC information requests

Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.

Why D2 blockade alone falls short in schizophrenia, and what neurotransmitter, genetic and neuroimaging research means for treatment-resistant patients.

A Delphi panel recommends screening for eating disorders before GLP-1 receptor agonist initiation.